BioSpace News Archive

Royal Philips announced the company has joined an initiative created by the Department of Health and Human Services, in partnership with the White House, to address climate action through the reduction of greenhouse gas emissions.

Albany College of Pharmacy and Health Sciences (ACPHS) announces the expansion of its Albany campus through the acquisition of a state-of-the-art medical and life sciences facility located at 150 New Scotland Avenue.

ClexBio, an early-stage biotech company developing next-generation tissue engineered grafts for transplant, is announcing the appointment of two new members to its Board of Directors.

Vast Therapeutics announces promising results with a nitric oxide releasing drug candidate under investigation for infections caused by Mycobacterium abscessus, a multi-drug resistant bacteria for which there are currently no FDA-approved treatments.

Endo International plc (NASDAQ: ENDP) announced today that a federal jury in Chicago, Illinois, has returned a verdict in favor of the Company’s subsidiaries Endo Pharmaceuticals Inc. and Endo Health Solutions Inc. (collectively Endo), in an antitrust trial.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the transaction between Intercept and Advanz Pharma announced on May 5, 2022, has now closed.

Scholar Rock (NASDAQ: SRRK), today announced an e-poster presentation by Thomas Crawford, M.D., on the design of the company’s ongoing SAPPHIRE Phase 3 clinical trial in spinal muscular atrophy (SMA) at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) in Brussels, Belgium (July 5 – 9, 2022).

MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 65,000 shares of the company’s common stock to two new employees.

TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 250,000 shares of TCR2’s common stock to 1 new executive employee on June 27, 2022 and an aggregate of 64,800 shares of TCR2’s common stock to 9 new non-executive employees on June 30, 2022.

Adicet Bio, Inc., a clinical-stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer, announced it granted inducement awards on June 30, 2022 under Adicet’s 2022 Inducement Plan as a material inducement to employment to ten individuals hired by Adicet in June 2022.